NCT01845337 2023-05-12
TOFFEE
University of Edinburgh
Phase 2 Completed
Clinical Trials
9 trialsNCT03111732 2021-12-03
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03231176 2020-11-19
Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer
ASLAN Pharmaceuticals
Phase 2 Completed
NCT01534637 2018-08-15
Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT00789958 2018-04-09
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
SWOG Cancer Research Network
Phase 2 Completed
NCT00033540 2017-09-12
S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma
SWOG Cancer Research Network
Phase 2 Completed
NCT02042443 2017-09-12
S1310
National Cancer Institute (NCI)
Phase 2 Completed
NCT01151761 2016-07-29
Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
Stanford University
Phase 2 Terminated
NCT00084942 2012-01-12
Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder
Roswell Park Cancer Institute
Phase 2 Completed